If we eliminated out-of-pocket costs, more patients would be able to access the medications they need. Branded drug volumes would likely go up, but increased drug company margins would make it possible for PBMs to drive further price competition in competitive drug classes, mitigating the impact of eliminating OOP costs on overall societal spending. We plan to model these dynamics.
Feel free to reach out with questions, concerns, or comments.
Contact us
